跳至主要内容
临床试验/NCT06396806
NCT06396806Enrolling By Invitation不适用

A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 1,072 人开始时间: 2024年5月6日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
1,072
试验地点
1
主要终点
Disease-free survival rate

研究概览

简要总结

he purpose of this study is to explore the clinical outcomes of Indocyanine Green Tracer using in laparoscopic radical sigmoidectomy for sigmoid adenocarcinoma (cT2-T4a N0 M0,T1-T4a N+ M0).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 and 75 years old
  • Confirmed sigmoid adenocarcinoma cancer pathologically
  • Location of tumor: the sigmoid colon (descending colon from vertical to horizontal point) is the starting point of sigmoid colon, and the end point of sigmoid colon is at 15cm of anal margin.
  • CT showed sigmoid colon cancer: T3-4a N+ M0
  • Patients with non-local recurrence or distant metastasis;
  • no multiple colorectal cancer;
  • no neoadjuvant therapy;
  • physical conditions such as heart, lung, liver and kidney function can tolerate surgery.
  • Willing and able to provide written informed consent for participation in this study

排除标准

  • Complicated with other malignant tumors or previous history of malignant tumors;
  • patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc.;
  • patients with tumor invasion or involvement of adjacent organs requiring combined organ resection;
  • patients with poor anal function and incontinence before operation;
  • patients with inflammatory bowel disease or familial adenomatous polyposis
  • ASA grade ≥ IV and / or ECOG physical status score > 2;
  • patients with severe hepatorenal function, cardiopulmonary function, blood coagulation dysfunction or severe underlying diseases unable to tolerate surgery;
  • history of severe mental illness;
  • pregnant or lactating women;
  • patients with uncontrolled infection before operation;
  • patients with other clinical and laboratory conditions considered by some researchers should not participate in this trial.

结局指标

主要结局

Disease-free survival rate

时间窗: 3 years after the surgery

odisease-free survival was defined as the time from surgery to the time of recurrence or death from any cause

次要结局

  • Negative rate(14 days after the surgery)
  • mortality rate(30 days after the surgery)
  • Minimal Residual Disease, MRD(3 years after the surgery)
  • The correlation between the number of lymph nodes and 3-year overall survival rate and 3-year disease-free survival rate(3 years after the surgery)
  • Number of Metastasis Lymph Nodes(14 days after the surgery)
  • The rate of fluorescence(14 days after the surgery)
  • Total number of retrieved lymph nodes(14 days after the surgery)
  • The number of lymph nodes at each station(14 days after the surgery)
  • Positive rate(14 days after the surgery)
  • False positive rate(14 days after the surgery)
  • False negative rate(14 days after the surgery)
  • Morbidity rate(30 days after the surgery)
  • 5-year Overall survival rate(5 years after the surgery)
  • Pathological outcomes checklist(14 days after the surgery)
  • 3-year Overall survival rate(3 years after the surgery)
  • 5-year Disease-free survival rate(5 years after the surgery)
  • Local recurrence rate(3 years after the surgery)
  • Postoperative function (voiding function, sexual function) and quality of life(3 years after the surgery)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanhong Deng

Chief physician,Assistant to the dean

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验